Publications

Inhibition of phosphatidylinositol 3-kinase destabilizes Mycn protein and blocks malignant progression in neuroblastoma.

Chesler L, Schlieve C, Goldenberg DD, Kenney A, Kim G, McMillan A, Matthay KK, Rowitch D, Weiss WA

2006
The tumour suppressor Hippo acts with the NDR kinases in dendritic tiling and maintenance.

Emoto K, Parrish JZ, Jan LY, Jan YN

2006
The tumour suppressor Hippo acts with the NDR kinases in dendritic tiling and maintenance.

Emoto K, Parrish JZ, Jan LY, Jan YN

2006
Heterogeneity at the HLA-DRB1 locus and risk for multiple sclerosis.

Barcellos LF, Sawcer S, Ramsay PP, Baranzini SE, Thomson G, Briggs F, Cree BC, Begovich AB, Villoslada P, Montalban X, Uccelli A, Savettieri G, Lincoln RR, DeLoa C, Haines JL, Pericak-Vance MA, Compston A, Hauser SL, Oksenberg JR

2006
Heterogeneity at the HLA-DRB1 locus and risk for multiple sclerosis.

Barcellos LF, Sawcer S, Ramsay PP, Baranzini SE, Thomson G, Briggs F, Cree BC, Begovich AB, Villoslada P, Montalban X, Uccelli A, Savettieri G, Lincoln RR, DeLoa C, Haines JL, Pericak-Vance MA, Compston A, Hauser SL, Oksenberg JR

2006
Tissue injury regulates serotonin 1D receptor expression: implications for the control of migraine and inflammatory pain.

Ahn AH, Basbaum AI

2006
Tissue injury regulates serotonin 1D receptor expression: implications for the control of migraine and inflammatory pain.

Ahn AH, Basbaum AI

2006
Interleukin-2/interferon-alpha2a/13-retinoic acid-based chemoimmunotherapy in advanced renal cell carcinoma: results of a prospectively randomised trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN).

Atzpodien J, Kirchner H, Rebmann U, Soder M, Gertenbach U, Siebels M, Roigas J, Raschke R, Salm S, Schwindl B, Müller SC, Hauser S, Leiber C, Huland E, Heinzer H, Siemer S, Metzner B, Heynemann H, Fornara P, Reitz M

2006
Activation of NR2B-containing NMDA receptors is not required for NMDA receptor-dependent long-term depression.

Morishita W, Lu W, Smith GB, Nicoll RA, Bear MF, Malenka RC

2006
Interleukin-2/interferon-alpha2a/13-retinoic acid-based chemoimmunotherapy in advanced renal cell carcinoma: results of a prospectively randomised trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN).

Atzpodien J, Kirchner H, Rebmann U, Soder M, Gertenbach U, Siebels M, Roigas J, Raschke R, Salm S, Schwindl B, Müller SC, Hauser S, Leiber C, Huland E, Heinzer H, Siemer S, Metzner B, Heynemann H, Fornara P, Reitz M

2006

Pages